Calls for papers
-
RDD 2022 (May 1-5 in Orlando, Florida) will be the first major OINDP meeting to take place primarily in person since the beginning of the COVID-19 pandemic. According to Richard Dalby of RDD Online, organizers… Read more . . .
-
TFF Pharmaceuticals said that the company has entered into an additional Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Geneva Foundation for formulation of an intranasal dry powder… Read more . . .
-
The FDA has approved a generic version of AstraZeneca’s Symbicort budesonide / formoterol fumarate MDI from Mylan (now Viatris), the agency announced. The FDA tentatively approved the Mylan ANDA in March 2021 just after a… Read more . . .
-
Declaring that it is “determined to grow its portfolio in the complex generics space,” Novartis generics division Sandoz announced its acquisition of device device developer Coalesce Product Development. Coalesce’s inhaler technology include MDI, breath-actuated MDI,… Read more . . .
-
Researchers from the University of Liverpool have partnered with nebulizer maker Aerogen on a project called “Treatment of Respiratory Infections with inhaled AntimicrobiaLs” (TRIAL), which will develop inhaled therapies for the treatment of bacterial and… Read more . . .
-
Inhaler monitoring company Adherium has announced the submission of a 510(k) for a new Hailie sensor designed specifically for use with Ellipta DPIs. In September 2021, the FDA cleared another version of the next generation… Read more . . .
-
According to Optinose, the Phase 3 ReOpen1 trial of Xhance intranasal fluticasone propionate (OPN-375) in patients with chronic sinusitus met both of its primary endpoints, demonstrating statistically significant reduction in symptoms and in sinus inflammation… Read more . . .
-
Tonix Pharmaceuticals has provided updates on two formulations of its intranasal potentiated oxytocin. The company acquired the license for one of the formulations, TNX-1900 for the treatment of migraine, from Trigemina in June 2020. According… Read more . . .
-
Device maker HCmed Innovations has partnered with Formosa Laboratories and Formosa Pharmaceuticals to offer contract development and manufacturing services for inhaled drugs, HCmed announced. Formosa Laboratories already offers CDMO services for pharmaceutical products; the new… Read more . . .
-
In December 2021, inhaled drug developer Aerami Therapeutics announced that it would go public by merging with FoxWayne Enterprises Acquisition Corp, a special purpose acquisition company (SPAC). The two companies have now announced that the deal… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA